Masupirdine trial for agitation in Alzheimer’s dementia
Part of Brain & nervous system clinical trials.
This Phase 3 study tests masupirdine to see if it can reduce agitation in people with Alzheimer’s-type dementia. If you have Alzheimer’s dementia with confirmed agitation, joining could help researchers find better treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alzheimer’s-type dementia (not another dementia type)
- Your agitation has been confirmed using a standard agitation checklist used in cognitive disorders
- Your Mini-Mental State Examination (MMSE) score is 8 to 24 (including both ends)
- Your agitation is due to Alzheimer’s dementia, not pain, another mental health issue, or an episode of confusion from infection or other body problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.
This trial tests a skin patch that delivers a medicine called dexmedetomidine to help calm agitation in people with Alzheimer's disease. It might be an option for those living in a care facility who have had recent episodes of agitation.
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
This study tests an experimental medication, ITI-1284, to see if it can safely reduce agitation in people with Alzheimer's disease. Agitation can include restlessness, aggression, or irritability, and this drug aims to help manage those symptoms.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Hear when a new Agitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.